SOUTHBOROUGH, Mass., May 2, 2011 /PRNewswire/ -- SynapDx Corporation announced today that is has obtained an exclusive world-wide license to technology from Children's Hospital Boston to accelerate the Company's development of blood-based tests to enable the early detection of Autism Spectrum Disorders. The discoveries were developed through collaboration by leading Children's researchers, Dr. Louis Kunkel and Dr. Isaac Kohane. In 2010, SynapDx also obtained exclusive world-wide rights to blood-based autism detection technologies from George Washington University, based on the work of Dr. Valerie Hu.
Dr. Kunkel is the Director of Children's Genomics Program and is credited with the discovery of the cause of Duchenne/Becker muscular dystrophy. Recently, he has turned his research towards better understanding the underlying causes of autism spectrum disorders.
Dr. Kohane is the Director of the Informatics program at Children's. His work combines the power of genomics and computer science to better understand brain development in autism spectrum disorders.
About SynapDx Corporation
SynapDx's mission is to provide laboratory testing services to physicians who evaluate children for developmental disorders with the initial goal of enabling earlier detection of autism. Autism Spectrum Disorders are currently estimated to affect 1 in 110 children in the United States according to the Centers for Disease Control.
SynapDx was founded by Stanley Lapidus and closed a Series A round of venture funding in May 2010 from North Bridge Venture Partners, Bain Capital Ventures and General Catalyst Partners. SynapDx's corporate headquarters is located in Southborough, MA. For more information, please visit: www.synapdx.com.
|SOURCE SynapDx Corporation|
Copyright©2010 PR Newswire.
All rights reserved